Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials

[1] Collins AJ(2010)Excerpts from the US renal data system 2009 annual data report Am J Kidney Dis 55 S1-420

[2] Foley RN(2003)Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention Hypertension 42 1050-1065

[3] Herzog C(2001)Residual renal function and mortality risk in hemodialysis patients Am J Kidney Dis 38 85-90

[4] Chavers BM(2011)Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model Nephrol Dial Transplant 26 2978-2983

[5] Gilbertson D(2001)Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 629-636

[6] Ishani A(2007)Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study J Am Soc Nephrol 18 2766-2772

[7] Sarnak MJ(2016)Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials Am J Kidney Dis 67 728-741

[8] Levey AS(2006)Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study Nephrol Dial Transplant 21 2507-2512

[9] Schoolwerth AC(2006)Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 1318-1324

[10] Coresh J(2008)Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 501-506

[1] Collins AJ(2010)Excerpts from the US renal data system 2009 annual data report Am J Kidney Dis 55 S1-420

[2] Foley RN(2003)Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention Hypertension 42 1050-1065

[3] Herzog C(2001)Residual renal function and mortality risk in hemodialysis patients Am J Kidney Dis 38 85-90

[4] Chavers BM(2011)Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model Nephrol Dial Transplant 26 2978-2983

[5] Gilbertson D(2001)Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 629-636

[6] Ishani A(2007)Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study J Am Soc Nephrol 18 2766-2772

[7] Sarnak MJ(2016)Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials Am J Kidney Dis 67 728-741

[8] Levey AS(2006)Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study Nephrol Dial Transplant 21 2507-2512

[9] Schoolwerth AC(2006)Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 1318-1324

[10] Coresh J(2008)Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 501-506